search for




 

Journal of Obesity & Metabolic Syndrome 2019;28(1):18-29 https://doi.org/10.7570/jomes.2019.28.1.18
The Effects of Hypoglycemic Agents on Non-alcoholic Fatty Liver Disease: Focused on Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
Published online March 30, 2019
© 2019 Korean Society for the Study of Obesity

Chan-Hee Jung, Ji-Oh Mok*

Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea
*Ji-Oh Mok, https://orcid.org/0000-0003-4882-1206, Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, 170 Jomaru-ro, Wonmi-gu, Bucheon 14584, Korea, Tel: +82-32-621-5158, Fax: +82-32-621-5016, E-mail: hanna@schmc.ac.kr
Received December 30, 2018; Revised January 24, 2019; Accepted January 29, 2019.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract

The only known, effective intervention for non-alcoholic fatty liver disease (NAFLD) is weight loss, and there is no approved pharmacotherapy. Recently, new hypoglycemic agents, such as sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs), and their effects on NAFLD have received substantial interest. Herein, we review the currently available human studies regarding the effects of SGLT2 inhibitors and GLP-1RAs on NAFLD/non-alcoholic steatohepatitis in patients with type 2 diabetes mellitus, and we describe the possible mechanisms explaining the positive effects of these agents on NAFLD.

Keywords : Sodium-glucose cotransporter 2 inhibitor, Glucagon-like peptide-1 receptor agonist, Non-alcoholic fatty liver disease, Type 2 diabetes mellitus


March 2019, 28 (1)
Full Text(PDF) Free

Cited By Articles
  • CrossRef (0)

Author ORCID Information

Services

Social Network Service